Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a caucasian cohort

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1546-1552

  Sun, Tong ^a   Lee, Gwo Shu Mary ^a   Oh, William K ^a   Freedman, Matthew L ^a   Pomerantz, Mark ^a   Pienta, Kenneth J ^b   Kantoff, Philip W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CAUCASIAN; CC CHEMOKINE LIGAND 2 GENE; CLASSIFICATION; CONTROLLED STUDY; D'AMICO RISK CLASSIFICATION; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HAPLOTYPE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHEMOKINE CCL2; COHORT STUDIES; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK;

EID: 79952718904     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2015     Document Type: Article

References (38)

1. Hippe A, Homey B, Mueller-Homey A. Chemokines. Recent Results-Cancer Res 2010;180:35-50.
2. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010;16:133-44.
3. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29:313-26.
4. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004;14:149-54. (Pubitemid 38586739)
5. Craig MJ, Loberg RD. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev 2006;25:611-9. (Pubitemid 46071867)
6. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010;102:522-8.
7. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010;21:41-8.
8. Sáenz-López P, Carretero R, Cózar JM, Romero JM, Canton J, Vilchez JR, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 2008;8:382.
9. Tse KP, Tsang NM, Chen KD, Li HP, Liang Y, Hsueh C, et al. MCP-1 Promoter Polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res 2007;13:6320-6. (Pubitemid 350075020)
10. Ghilardi G, Biondi ML, La Torre A, Battaglioli L, Scorza R. Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin Chem 2005;51:452-5. (Pubitemid 40175819)
11. Navratilova Z. Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006;150:191-204.
12. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr, et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005;112:1113-20. (Pubitemid 41216117)
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-249
14. Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008;9:211-28. (Pubitemid 351233730)
15. Witte JS. Prostate cancer genomics: towards a new understanding. Nat Rev Genet 2009;10:77-82.
16. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26:842-7. (Pubitemid 351398074)
17. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009;69:1195-205.
18. Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006;5:61-6.
19. Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, et al. Inherited variations in AR, ESR1 and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev 2010;19;1871-8.
20. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006;2:e190.
21. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280: 969-74. (Pubitemid 28445094)
22. Qin ZS, Niu T, Liu JS. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002;71:1242-7. (Pubitemid 35305248)
23. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-5. (Pubitemid 40202029)
24. Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 2009;11:1235-42.
25. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007;9:556-62. (Pubitemid 47121829)
26. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007;67:9417-24. (Pubitemid 47535932)
27. Nakamura Y. DNA variations in human and medical genetics: 25 years of my experience. J Hum Genet 2009;54:1-8.
28. Joven J, Coll B, Tous M, Ferré N, Alonso-Villaverde C, Parra S, et al. The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis. Clin Chim Acta 2006;368:114-9. (Pubitemid 43776035)
29. M€uhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003;125:1085-93. (Pubitemid 37193455)
30. Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, Von Feldt JM. Monocyte chemoattractant protein-1: plasma concentrations and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 2007;34:740-6. (Pubitemid 46641380)
31. Wright EK Jr, Page SH, Barber SA, Clements JE. Prep1/Pbx2 complexes regulate CCL2 expression through the -2578 guanine polymorphism. Genes Immun 2008;9:419-30.
32. Thye T, Nejentsev S, Intemann CD, Browne EN, Chinbuah MA, Gyapong J, et al. MCP-1 promoter variant -362C associated with protection from pulmonary tuberculosis in Ghana, West Africa. Hum Mol Genet 2009;18:381-8.
33. Nyquist P, Zhang J, De Graba TJ. The -928 G/C and -362 G/C single-nucleotide polymorphisms in the promoter of MCP-1: increased transcriptional activity and novel binding sites. Cerebrovasc Dis 2010;29:242-7.
34. Matys V, Fricke E, Geffers R, G€ossling E, Haubrock M, Hehl R, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 2003;31:374-8. (Pubitemid 36150406)
35. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358:910-9. (Pubitemid 351397090)
36. Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, Catalona WJ. Pathological outcomes associated with the 17q prostate cancer risk variants. J Urol 2009;181:2502-7.
37. Levin AM, Machiela MJ, Zuhlke KA, Ray AM, Cooney KA, Douglas JA. Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. Cancer Res 2008;68:6492-5.
38. Bao BY, Pao JB, Lin VC, Huang CN, Chang TY, Lan YH, et al. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta 2010;411:1232-1237.